gamma-aminobutyric acid has been researched along with Tourette Syndrome in 31 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Tourette Syndrome: A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim is to study the effects of gastrodin (GA) on striatal inflammation and oxidative stress in rats with Tourette syndrome (TS)." | 7.91 | Gastrodin alleviates Tourette syndrome via Nrf-2/HO-1/HMGB1/NF-кB pathway. ( Huang, Y; Long, H; Ruan, J; Wang, C; Zhang, M, 2019) |
| "Many studies have indicated that a variety of neurotransmitters are implicated in the pathophysiology of Tourette syndrome (TS), including dopamine (DA), serotonin (5-TH), homovanillic acid (HVA), and gamma-amino butyric acid (GABA)." | 5.16 | Effects of Chinese herbal medicine Ningdong granule on regulating dopamine (DA)/serotonin (5-TH) and gamma-amino butyric acid (GABA) in patients with Tourette syndrome. ( Li, A; Li, J; Qi, F; Wang, S; Zhao, L, 2012) |
| "The aim is to study the effects of gastrodin (GA) on striatal inflammation and oxidative stress in rats with Tourette syndrome (TS)." | 3.91 | Gastrodin alleviates Tourette syndrome via Nrf-2/HO-1/HMGB1/NF-кB pathway. ( Huang, Y; Long, H; Ruan, J; Wang, C; Zhang, M, 2019) |
| "We found that NDG could ameliorate tics significantly according the YGTSS score." | 2.77 | Effects of Chinese herbal medicine Ningdong granule on regulating dopamine (DA)/serotonin (5-TH) and gamma-amino butyric acid (GABA) in patients with Tourette syndrome. ( Li, A; Li, J; Qi, F; Wang, S; Zhao, L, 2012) |
| "Tics are the essential component of a variety of disorders, notably Tourette syndrome." | 2.41 | The treatment of tics. ( Singer, HS, 2001) |
| "Because the mere presence of tics does not require therapeutic intervention, criteria are essential for determining a functional disability." | 2.41 | The treatment of tics. ( Singer, HS, 2001) |
| "A brief review of Gilles de la Tourette's disease is presented." | 2.36 | Behavioral and clinical profiles of Tourette's disease: a comprehensive overview. ( Carlson, JC; Messiha, FS, 1983) |
| "More severe urges correlate with worse tics and can render behavioral therapies less effective." | 1.91 | From urges to tics in children with Tourette syndrome: associations with supplementary motor area GABA and right motor cortex physiology. ( Cecil, KM; Edden, RAE; Gilbert, DL; Horn, PS; Huddleston, DA; Jackson, HS; Larsh, TR; Mostofsky, SH; Wu, SW, 2023) |
| "Within the Tourette disorder group, we examined correlations between γ-aminobutyric acid levels and tic severity and tic-related impairment, as well as anxiety and depression severity." | 1.43 | Decreased Anterior Cingulate Cortex γ-Aminobutyric Acid in Youth With Tourette's Disorder. ( Coffey, BJ; Freed, RD; Gabbay, V; Kang, G; Mao, X; Shungu, DC; Weiduschat, N, 2016) |
| "Within the Tourette disorder group, γ-aminobutyric acid levels did not correlate with any clinical measures." | 1.43 | Decreased Anterior Cingulate Cortex γ-Aminobutyric Acid in Youth With Tourette's Disorder. ( Coffey, BJ; Freed, RD; Gabbay, V; Kang, G; Mao, X; Shungu, DC; Weiduschat, N, 2016) |
| "In orthostatic test, patients with Tourette syndrome demonstrated an unfavorable hypersympathicotonic type of cardiovascular system reaction." | 1.33 | [Autonomic cardiovascular regulation in patients with tics and Tourette syndrome]. ( Begasheva, OI; Kabanova, SA; Komarova, IB; Nazarova, EK; Zykov, VP, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (32.26) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| He, JL | 1 |
| Mikkelsen, M | 1 |
| Huddleston, DA | 2 |
| Crocetti, D | 2 |
| Cecil, KM | 2 |
| Singer, HS | 4 |
| Edden, RAE | 3 |
| Gilbert, DL | 2 |
| Mostofsky, SH | 3 |
| Puts, NAJ | 1 |
| Larsh, TR | 1 |
| Horn, PS | 1 |
| Wu, SW | 1 |
| Jackson, HS | 1 |
| Xi, L | 1 |
| Ji, X | 1 |
| Ji, W | 1 |
| Yang, Y | 1 |
| Zhang, Y | 1 |
| Long, H | 2 |
| Ruan, J | 1 |
| Zhang, M | 1 |
| Wang, C | 1 |
| Huang, Y | 1 |
| Mahone, EM | 1 |
| Puts, NA | 2 |
| Ryan, M | 1 |
| Tinaz, S | 1 |
| Belluscio, BA | 1 |
| Malone, P | 1 |
| van der Veen, JW | 1 |
| Hallett, M | 2 |
| Horovitz, SG | 1 |
| Lennington, JB | 1 |
| Coppola, G | 1 |
| Kataoka-Sasaki, Y | 1 |
| Fernandez, TV | 1 |
| Palejev, D | 1 |
| Li, Y | 1 |
| Huttner, A | 1 |
| Pletikos, M | 1 |
| Sestan, N | 1 |
| Leckman, JF | 4 |
| Vaccarino, FM | 3 |
| Draper, A | 2 |
| Stephenson, MC | 1 |
| Jackson, GM | 2 |
| Pépés, S | 1 |
| Morgan, PS | 1 |
| Morris, PG | 1 |
| Jackson, SR | 2 |
| Tübing, J | 1 |
| Münchau, A | 1 |
| Harris, AD | 1 |
| Nettles, C | 1 |
| Tommerdahl, M | 1 |
| Edden, RA | 1 |
| Dyke, K | 1 |
| Pépés, SE | 1 |
| Freed, RD | 1 |
| Coffey, BJ | 1 |
| Mao, X | 1 |
| Weiduschat, N | 1 |
| Kang, G | 1 |
| Shungu, DC | 1 |
| Gabbay, V | 1 |
| Lerner, A | 1 |
| Bagic, A | 1 |
| Simmons, JM | 1 |
| Mari, Z | 1 |
| Bonne, O | 1 |
| Xu, B | 1 |
| Kazuba, D | 1 |
| Herscovitch, P | 1 |
| Carson, RE | 1 |
| Murphy, DL | 1 |
| Drevets, WC | 1 |
| Wang, S | 1 |
| Qi, F | 1 |
| Li, J | 1 |
| Zhao, L | 1 |
| Li, A | 1 |
| Kalanithi, PS | 2 |
| Zheng, W | 1 |
| Kataoka, Y | 1 |
| DiFiglia, M | 1 |
| Grantz, H | 1 |
| Saper, CB | 1 |
| Schwartz, ML | 1 |
| Zykov, VP | 1 |
| Komarova, IB | 1 |
| Nazarova, EK | 1 |
| Begasheva, OI | 1 |
| Kabanova, SA | 1 |
| Rothenberger, A | 1 |
| Di Cristo, G | 1 |
| Plessen, KJ | 1 |
| Royal, JM | 1 |
| Peterson, BS | 1 |
| Coyle, JT | 1 |
| Singer, H | 1 |
| Beaulieu, M | 1 |
| Johnston, MV | 1 |
| van Woert, MH | 1 |
| Rosenbaum, D | 1 |
| Enna, SJ | 1 |
| Messiha, FS | 1 |
| Carlson, JC | 1 |
| Riddle, MA | 1 |
| Toru, M | 1 |
| Achar, VS | 1 |
| Welch, KM | 1 |
| Chabi, E | 1 |
| Bartosh, K | 1 |
| Meyer, JS | 1 |
| Gonge, M | 1 |
| Barbeau, A | 1 |
| Sandyk, R | 2 |
| Gillman, MA | 1 |
| Stahl, SM | 1 |
| Thornton, JE | 1 |
| Simpson, ML | 1 |
| Berger, PA | 1 |
| Napoliello, MJ | 1 |
| Mondrup, K | 1 |
| Dupont, E | 1 |
| Braendgaard, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI[NCT05232955] | 40 participants (Anticipated) | Observational | 2022-02-28 | Not yet recruiting | |||
| Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI[NCT05233306] | 60 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder[NCT03564132] | Phase 2 | 38 participants (Actual) | Interventional | 2018-06-16 | Completed | ||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
9 reviews available for gamma-aminobutyric acid and Tourette Syndrome
| Article | Year |
|---|---|
Inhibition, Disinhibition, and the Control of Action in Tourette Syndrome.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Inhibition, Psychological; Tourette Syndrome | 2015 |
Annotation: Tourette syndrome: a relentless drumbeat--driven by misguided brain oscillations.
Topics: Basal Ganglia; Brain; Child; Cortical Synchronization; gamma-Aminobutyric Acid; Humans; Interneurons | 2006 |
Development of cortical GABAergic circuits and its implications for neurodevelopmental disorders.
Topics: Autistic Disorder; Brain Diseases; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; N | 2007 |
Behavioral and clinical profiles of Tourette's disease: a comprehensive overview.
Topics: Acetylcholine; Dopamine; gamma-Aminobutyric Acid; Humans; Lithium; Lithium Carbonate; Norepinephrine | 1983 |
Tourette's syndrome: when habit-forming systems form habits of their own?
Topics: Animals; Autoimmunity; Basal Ganglia; Cerebral Cortex; Disease Models, Animal; gamma-Aminobutyric Ac | 2000 |
The treatment of tics.
Topics: Adrenergic alpha-Agonists; Androgen Antagonists; Anti-Bacterial Agents; Antipsychotic Agents; Autoim | 2001 |
[Abnormal neurotransmission in neurological diseases (author's transl)].
Topics: Acetylcholine; Animals; Antiparkinson Agents; Corpus Striatum; Dementia; Dopamine; Female; gamma-Ami | 1979 |
[Gilles de la Tourette's disease].
Topics: Antiparkinson Agents; Brain; Diagnosis, Differential; Diagnostic Errors; gamma-Aminobutyric Acid; Ha | 1977 |
The endogenous opioid system in neurological disorders of the basal ganglia.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clonidine; Endorphins; gamma-Aminobutyric Aci | 1985 |
1 trial available for gamma-aminobutyric acid and Tourette Syndrome
| Article | Year |
|---|---|
Effects of Chinese herbal medicine Ningdong granule on regulating dopamine (DA)/serotonin (5-TH) and gamma-amino butyric acid (GABA) in patients with Tourette syndrome.
Topics: Adolescent; Child; Dopamine; Drugs, Chinese Herbal; Enzyme-Linked Immunosorbent Assay; Female; gamma | 2012 |
21 other studies available for gamma-aminobutyric acid and Tourette Syndrome
| Article | Year |
|---|---|
Frequency and Intensity of Premonitory Urges-to-Tic in Tourette Syndrome Is Associated With Supplementary Motor Area GABA+ Levels.
Topics: Child; Child, Preschool; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Infant; Motor Cortex; Senso | 2022 |
From urges to tics in children with Tourette syndrome: associations with supplementary motor area GABA and right motor cortex physiology.
Topics: Child; Child, Preschool; gamma-Aminobutyric Acid; Humans; Inhibition, Psychological; Motor Cortex; T | 2023 |
Jing-an oral liquid alleviates Tourette syndrome via the NMDAR/MAPK/CREB pathway
Topics: Animals; Cyclic AMP Response Element-Binding Protein; gamma-Aminobutyric Acid; Glutamic Acid; Male; | 2022 |
Gastrodin alleviates Tourette syndrome via Nrf-2/HO-1/HMGB1/NF-кB pathway.
Topics: Animals; Benzyl Alcohols; Corpus Striatum; Cytokines; gamma-Aminobutyric Acid; Glucosides; Glutamic | 2019 |
GABA and glutamate in children with Tourette syndrome: A
Topics: Adult; Case-Control Studies; Child; Child, Preschool; Corpus Striatum; Female; gamma-Aminobutyric Ac | 2018 |
Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging.
Topics: Adolescent; Adult; Beta Rhythm; Brain Mapping; Creatine; Female; gamma-Aminobutyric Acid; Humans; Ma | 2014 |
Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging.
Topics: Adolescent; Adult; Beta Rhythm; Brain Mapping; Creatine; Female; gamma-Aminobutyric Acid; Humans; Ma | 2014 |
Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging.
Topics: Adolescent; Adult; Beta Rhythm; Brain Mapping; Creatine; Female; gamma-Aminobutyric Acid; Humans; Ma | 2014 |
Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging.
Topics: Adolescent; Adult; Beta Rhythm; Brain Mapping; Creatine; Female; gamma-Aminobutyric Acid; Humans; Ma | 2014 |
Transcriptome Analysis of the Human Striatum in Tourette Syndrome.
Topics: Acetylcholine; Adult; Aged; Aged, 80 and over; DNA Copy Number Variations; Female; gamma-Aminobutyri | 2016 |
Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome.
Topics: Adolescent; Corpus Callosum; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscop | 2014 |
Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome.
Topics: Adolescent; Corpus Callosum; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscop | 2014 |
Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome.
Topics: Adolescent; Corpus Callosum; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscop | 2014 |
Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome.
Topics: Adolescent; Corpus Callosum; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscop | 2014 |
Cortical GABAergic activity: a mediator of tic control?
Topics: Corpus Callosum; Female; gamma-Aminobutyric Acid; Humans; Male; Motor Cortex; Tourette Syndrome | 2015 |
Reduced GABAergic inhibition and abnormal sensory symptoms in children with Tourette syndrome.
Topics: Adaptation, Physiological; Cerebral Cortex; Child; Female; gamma-Aminobutyric Acid; Humans; Magnetic | 2015 |
Decreased Anterior Cingulate Cortex γ-Aminobutyric Acid in Youth With Tourette's Disorder.
Topics: Adolescent; Biomarkers; Child; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Magnetic Reso | 2016 |
Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.
Topics: Adult; Brain; Carbon Isotopes; Case-Control Studies; Female; Flumazenil; GABA Modulators; gamma-Amin | 2012 |
Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.
Topics: Adult; Brain; Carbon Isotopes; Case-Control Studies; Female; Flumazenil; GABA Modulators; gamma-Amin | 2012 |
Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.
Topics: Adult; Brain; Carbon Isotopes; Case-Control Studies; Female; Flumazenil; GABA Modulators; gamma-Amin | 2012 |
Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.
Topics: Adult; Brain; Carbon Isotopes; Case-Control Studies; Female; Flumazenil; GABA Modulators; gamma-Amin | 2012 |
Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome.
Topics: Adult; Aged; Basal Ganglia; Caudate Nucleus; Cell Count; Cell Movement; gamma-Aminobutyric Acid; Glo | 2005 |
[Autonomic cardiovascular regulation in patients with tics and Tourette syndrome].
Topics: Anti-Dyskinesia Agents; Anticonvulsants; Autonomic Nervous System Diseases; Child; Clonazepam; Femal | 2005 |
Neuroimaging of tic disorders with co-existing attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Caudate Nucleus; Ch | 2007 |
Development of central neurotransmitter-specified neuronal systems: implications for pediatric neuro-psychiatric disorders.
Topics: Afferent Pathways; Animals; Brain Damage, Chronic; Cats; Central Nervous System; Cerebral Cortex; Ch | 1984 |
Overview of pharmacological approaches to therapy for Tourette syndrome.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Antipsychotic Agents; Child; Clonidine; Corpus Striatum; Fem | 1982 |
Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease.
Topics: Aminobutyrates; Cerebrovascular Disorders; Dementia; Epilepsy, Post-Traumatic; Epilepsy, Temporal Lo | 1976 |
The endogenous opioid system in Gilles de la Tourette syndrome.
Topics: Acetylcholine; Dopamine; Endorphins; gamma-Aminobutyric Acid; Humans; Models, Biological; Neurotrans | 1986 |
Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.
Topics: Adult; Aged; Aminocaproates; Confusion; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; H | 1985 |
Progabide in the treatment of hyperkinetic extrapyramidal movement disorders.
Topics: Adolescent; Adult; Aged; Athetosis; Basal Ganglia Diseases; Child; Chorea; Female; gamma-Aminobutyri | 1985 |